StreetInsider.com News Articles

Xeris Announces Details for XP-8121 Program Overview Webinar

Wed, 26 Aug 2026 07:30:00 -0400

Webinar to Highlight Unmet Needs in Hypothyroidism, Market Opportunity, and Planned Phase 3 Program for XP-8121

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for a dedicated Program Overview webinar for XP-8121, the Company’s Phase 3-ready, once-weekly subcutaneous levothyroxine injection in development for the treatment of hypothyroidism.

The XP-8121 webinar will take place on Wednesday, September 9, 2026, at 10 a.m. ET and will feature a leading endocrinologist, alongside members of the Xeris program team.

Xeris Announces Details for XP-8121 Program Overview Webinar

Wed, 26 Aug 2026 07:30:00 -0400

Webinar to Highlight Unmet Needs in Hypothyroidism, Market Opportunity, and Planned Phase 3 Program for XP-8121

The XP-8121 webinar will take place on Wednesday, September 9, 2026, at 10 a.m. ET and will feature a leading endocrinologist, alongside members of the Xeris program team.

Xeris Announces Details for XP-8121 Program Overview Webinar

Wed, 26 Aug 2026 07:30:00 -0400

Webinar to Highlight Unmet Needs in Hypothyroidism, Market Opportunity, and Planned Phase 3 Program for XP-8121

The XP-8121 webinar will take place on Wednesday, September 9, 2026, at 10 a.m. ET and will feature a leading endocrinologist, alongside members of the Xeris program team.

Xeris Announces Details for XP-8121 Program Overview Webinar

Wed, 26 Aug 2026 07:30:00 -0400

Webinar to Highlight Unmet Needs in Hypothyroidism, Market Opportunity, and Planned Phase 3 Program for XP-8121

The XP-8121 webinar will take place on Wednesday, September 9, 2026, at 10 a.m. ET and will feature a leading endocrinologist, alongside members of the Xeris program team.

Form 4 Xeris Biopharma Holdings For: Aug 01 Filed by: Shannon John Patrick Jr

Fri, 21 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260821/26961696.html

Form 4 Xeris Biopharma Holdings For: Aug 01 Filed by: Shannon John Patrick Jr

Fri, 21 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260821/26961696.html

Form 4 Xeris Biopharma Holdings For: Aug 01 Filed by: McCulloch Kevin

Fri, 21 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260821/26961610.html

Form 4 Xeris Biopharma Holdings For: Aug 01 Filed by: McCulloch Kevin

Fri, 21 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260821/26961610.html

Form 4 Xeris Biopharma Holdings For: Aug 12 Filed by: Pieper Steven

Wed, 12 Aug 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260812/26913751.html

Form 4 Xeris Biopharma Holdings For: Aug 12 Filed by: Pieper Steven

Wed, 12 Aug 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260812/26913751.html

Form 144 Xeris Biopharma Holdings Filed by: Pieper Steven

Wed, 12 Aug 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260812/26913614.html

Form 144 Xeris Biopharma Holdings Filed by: Pieper Steven

Wed, 12 Aug 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260812/26913614.html

Form 10-Q Xeris Biopharma Holdings For: Jun 30

Thu, 06 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260806/26883825.html

Form 10-Q Xeris Biopharma Holdings For: Jun 30

Thu, 06 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260806/26883825.html

Form 8-K Xeris Biopharma Holdings For: Aug 06

Thu, 06 Aug 2026 07:13:00 -0400

si-local-file:///var/storage/secattach/20260806/26878618.html

Form 8-K Xeris Biopharma Holdings For: Aug 06

Thu, 06 Aug 2026 07:13:00 -0400

si-local-file:///var/storage/secattach/20260806/26878618.html

Xeris Pharmaceuticals Inc. (XERS) Misses Q2 EPS by 19c; Offers Guidance

Thu, 06 Aug 2026 07:09:27 -0400

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q2 EPS of ($0.18), $0.19 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $92.1 million versus the consensus estimate of $90.29 million.

GUIDANCE:

Xeris Pharmaceuticals Inc. sees FY2026 revenue of $385-390 million, versus the consensus of $385.9 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

Xeris Pharmaceuticals Inc. (XERS) Misses Q2 EPS by 19c; Offers Guidance

Thu, 06 Aug 2026 07:09:27 -0400

GUIDANCE:

Xeris Pharmaceuticals Inc. sees FY2026 revenue of $385-390 million, versus the consensus of $385.9 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

Xeris Biopharma Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 07:00:00 -0400

Total revenue increased to over $92 million

Net product revenue increased 34% year-over-year to over $91 million

Recorlev net revenue increased 81% year-over-year to approximately $57 million

Tightens full-year 2026 total revenue guidance to $385 million to $390 million

Conference call and webcast today at 8:30 a.m. ET

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced its financial results for the second quarter ended June 30, 2026.

"The second quarter was another strong period for Xeris,

Xeris Biopharma Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 07:00:00 -0400

Total revenue increased to over $92 million

Net product revenue increased 34% year-over-year to over $91 million

Recorlev net revenue increased 81% year-over-year to approximately $57 million

Tightens full-year 2026 total revenue guidance to $385 million to $390 million

Conference call and webcast today at 8:30 a.m. ET

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced its financial results for the second quarter ended June 30, 2026.

"The second quarter was another strong period for Xeris,

Xeris Biopharma Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 07:00:00 -0400

Total revenue increased to over $92 million

Net product revenue increased 34% year-over-year to over $91 million

Recorlev net revenue increased 81% year-over-year to approximately $57 million

Tightens full-year 2026 total revenue guidance to $385 million to $390 million

Conference call and webcast today at 8:30 a.m. ET

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced its financial results for the second quarter ended June 30, 2026.

"The second quarter was another strong period for Xeris,

Xeris Biopharma Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 07:00:00 -0400

Total revenue increased to over $92 million

Net product revenue increased 34% year-over-year to over $91 million

Recorlev net revenue increased 81% year-over-year to approximately $57 million

Tightens full-year 2026 total revenue guidance to $385 million to $390 million

Conference call and webcast today at 8:30 a.m. ET

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced its financial results for the second quarter ended June 30, 2026.

"The second quarter was another strong period for Xeris,

Form 4 Xeris Biopharma Holdings For: Aug 03 Filed by: McCulloch Kevin

Tue, 04 Aug 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260804/26868163.html

Form 4 Xeris Biopharma Holdings For: Aug 03 Filed by: McCulloch Kevin

Tue, 04 Aug 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260804/26868163.html

Form 4 Xeris Biopharma Holdings For: Aug 03 Filed by: Hecht Beth

Tue, 04 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260804/26867984.html